15-SORRENTO-Therapeutics-Logo-FINAL.png
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC™ in Hospitalized COVID-19 Patients With Acute Respiratory Distress Syndrome
May 20, 2021 09:00 ET | Sorrento Therapeutics, Inc.
Brazil Phase 2 Pivotal clinical trial of COVI-MSC is now authorized to proceed.The study will compare therapy using mesenchymal stem cells to placebo (and standard of care) in 100 COVID-19 patients...
TrevenaLogo.jpg
Trevena Announces TRV027 Selected by NIH-Funded ACTIV Initiative For COVID-19 Trial
May 06, 2021 07:03 ET | Trevena Inc.
-- Vanderbilt University Medical Center (VUMC) is coordinating multiple-arm, multi-site ACTIV-4d study targeting RAAS TRV027 to be dosed in ~300 COVID-19 patients -- CHESTERBROOK, Pa., May 06,...
TrevenaLogo.jpg
Trevena Announces TRV027 Selected for Study in Global REMAP-CAP Trial in COVID-19 Patients
April 21, 2021 07:00 ET | Trevena Inc.
-- REMAP-CAP is led by experts in pandemic response and builds upon a worldwide clinical trial network evaluating treatments for COVID-19 Interim review of Imperial College London TRV027 study data...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces Positive Results of Phase 1b Study of COVI-MSC™ Treatment of ICU Covid-19 Patients, Achieving 100% (10 out 10) Discharge Rate
April 20, 2021 09:00 ET | Sorrento Therapeutics, Inc.
The target enrollment of 10 patients with acute respiratory failure due to COVID-19 has been accomplished.All 10 patients were discharged from hospital within three days after their last COVI-MSC...
Angion_2IN-02.jpg
Angion Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
March 30, 2021 16:05 ET | Angion Biomedica Corp.
UNIONDALE, N.Y., March 30, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces Updated Positive Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
March 25, 2021 15:58 ET | Sorrento Therapeutics, Inc.
All nine patients with acute respiratory failure due to COVID-19 discharged from hospital within days after 3rd COVI-MSC infusionPreparations are ongoing for initiating Phase 2 placebo-controlled...
Angion_2IN-02.jpg
Angion Completes Enrollment in Phase 2 Study of ANG-3777 for Acute Lung Injury in Patients with COVID-19 Associated Pneumonia
March 25, 2021 00:05 ET | Angion Biomedica Corp.
UNIONDALE, N.Y., March 25, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ: ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Update to 01/26/21 COVI-MSC™ Press Release: Fourth Patient Also Released From Hospital Following Third Infusion of Stem Cells
January 31, 2021 17:28 ET | Sorrento Therapeutics, Inc.
Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC starting Monday (January 25, 2021) and discharged last Friday (January...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
January 26, 2021 19:09 ET | Sorrento Therapeutics, Inc.
First three patients discharged from Hospital ICU within 8 days from initial IV administration  No infusion-related adverse events noted for any patient treated to date  SAN DIEGO, Jan. 26, 2021 ...
logo.png
Arch Biopartners Receives Government of Canada Funding to Support Phase II Therapeutic Trial of Metablok for COVID-19
December 15, 2020 12:52 ET | Arch Biopartners
Government of Canada contribution up to $6.7 MillionFunding from the department of Innovation, Science and Economic Development through the Strategic Innovation Fund and part of the Government of...